TARSUS PHARMACEUTICALS INC's ticker is TARS and the CUSIP is 87650L103. A total of 41 filers reported holding TARSUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $10,642,683 | +31.0% | 391,563 | +75.1% | 0.00% | 0.0% |
| Q1 2024 | $8,126,733 | +310.0% | 223,569 | +128.4% | 0.00% | – |
| Q4 2023 | $1,981,928 | +162.6% | 97,873 | +134.3% | 0.00% | – |
| Q2 2023 | $754,766 | -1.9% | 41,769 | -31.7% | 0.00% | – |
| Q1 2023 | $769,008 | -7.5% | 61,178 | +7.8% | 0.00% | – |
| Q4 2022 | $831,721 | +19.5% | 56,734 | +39.5% | 0.00% | – |
| Q3 2022 | $696,000 | +11.9% | 40,663 | -4.6% | 0.00% | – |
| Q2 2022 | $622,000 | +32.1% | 42,617 | +52.3% | 0.00% | – |
| Q1 2022 | $471,000 | -12.5% | 27,982 | +17.1% | 0.00% | – |
| Q4 2021 | $538,000 | -12.7% | 23,904 | -16.5% | 0.00% | – |
| Q3 2021 | $616,000 | -30.2% | 28,614 | -6.0% | 0.00% | – |
| Q2 2021 | $882,000 | -6.5% | 30,428 | +4.0% | 0.00% | – |
| Q1 2021 | $943,000 | +17.7% | 29,259 | +51.1% | 0.00% | – |
| Q4 2020 | $801,000 | – | 19,367 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,089,856 | $35,778,000 | 4.39% |
| Vivo Capital, LLC | 2,262,200 | $38,729,000 | 4.28% |
| Cormorant Asset Management, LP | 1,971,422 | $33,751,000 | 2.36% |
| Frazier Life Sciences Management, L.P. | 1,787,527 | $30,602,000 | 2.36% |
| Sands Capital Ventures, LLC | 260,000 | $4,451,000 | 1.29% |
| COWEN AND COMPANY, LLC | 522,329 | $8,942,000 | 0.86% |
| RTW INVESTMENTS, LP | 2,023,179 | $34,637,000 | 0.80% |
| Perceptive Advisors | 1,296,416 | $22,194,000 | 0.64% |
| Ghost Tree Capital, LLC | 120,000 | $2,054,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,324,214 | $22,671,000 | 0.45% |